Preferred Label : cilgavimab and tixagevimab drug combination;
MeSH synonym : cilgavimab and tixagevimab antibody combination; cilgavimab and tixagevimab mixture; cilgavimab, tixagevimab drug combination; tixagevimab and cilgavimab mixture; tixagevimab and cilgavimab antibody combination; tixagevimab and cilgavimab drug combination;
MeSH hyponym : AZD-7442; AZD1061 and AZD8895; AZD 7442;
Origin ID : C000714168;
UMLS CUI : C5543888;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
https://ansm.sante.fr/tableau-acces-derogatoire/tixagevimab-150-mg-cilgavimab-150-mg-solution-injectable-evusheld
2023
false
false
false
France
French
summary of product characteristics
package leaflet
cilgavimab and tixagevimab drug combination
Evusheld
drug combinations
cilgavimab
tixagevimab and cilgavimab
tixagevimab
COVID-19
COVID-19
adult
adolescent
Post-Exposure prophylaxis
risk factors
guidelines for drug use
immunologic deficiency syndromes
injections, intramuscular
SARS Coronavirus 2 B.1.1.529
SARS-CoV-2 variants
---
https://www.inesss.qc.ca/covid-19/traitements-specifiques-a-la-covid-19/tixagevimab-/-cilgavimab-evusheld-en-prophylaxie-preexposition.html
2022
false
false
false
Canada
COVID-19
drug evaluation
Pre-Exposure Prophylaxis
cilgavimab and tixagevimab drug combination
prophylactic treatment, nos
cilgavimab
Evusheld
tixagevimab
---
https://recalls-rappels.canada.ca/fr/avis-rappel/evusheld-tixagevimab-et-cilgavimab-injectables-risque-echec-prophylaxie-ou-du
2022
false
false
false
Canada
French
English
pharmacovigilance note
canada
drug resistance, viral
cilgavimab and tixagevimab drug combination
drug combinations
tixagevimab
cilgavimab
tixagevimab and cilgavimab
antibodies, monoclonal
antiviral agents
Evusheld
injections, intramuscular
COVID-19
COVID-19
Pre-Exposure Prophylaxis
SARS-CoV-2 variants
---
https://www.has-sante.fr/jcms/p_3324748/fr/evusheld-tixagevimab/cilgavimab-150-mg-/-150-mg
2022
false
false
false
France
COVID-19
Pre-Exposure Prophylaxis
Evusheld
cilgavimab and tixagevimab drug combination
adult
adolescent
treatment outcome
insurance, health, reimbursement
drug combinations
cilgavimab
tixagevimab
antiviral agents
guidelines for drug use
evaluation of the transparency committee
---
https://ansm.sante.fr/actualites/traitements-contre-le-covid-19-les-conditions-dacces-et-dutilisation-devusheld-evoluent
2022
false
false
false
France
French
guidelines for drug use
COVID-19
Evusheld
cilgavimab and tixagevimab drug combination
adult
adolescent
immunocompromised host
Pre-Exposure Prophylaxis
COVID-19
SARS-CoV-2 variants
SARS-CoV-2 Omicron variant infection
SARS Coronavirus 2 B.1.1.529
---
https://www.has-sante.fr/jcms/p_3383238/fr/evusheld-tixagevimab/cilgavimab-covid-19-adultes-et-adolescents
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, intramuscular
antiviral agents
cilgavimab
tixagevimab
drug combinations
tixagevimab and cilgavimab
package leaflet
summary of product characteristics
guidelines for drug use
evaluation of the transparency committee
adolescent
COVID-19
adult
Evusheld
cilgavimab and tixagevimab drug combination
---
https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld
2022
false
false
false
Netherlands
French
English
cilgavimab and tixagevimab drug combination
cilgavimab and tixagevimab drug combination
drug combinations
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tixagevimab and cilgavimab
adult
adolescent
COVID-19
aged
drug approval
europe
pregnancy
breast feeding
injections, intramuscular
continuity of patient care
spike protein, SARS-CoV-2
product surveillance, postmarketing
dna, recombinant
Pre-Exposure Prophylaxis
---
https://www.has-sante.fr/jcms/p_3352197/fr/evusheld-tixagevimab/cilgavimab-covid-19
2022
false
false
false
France
cilgavimab
tixagevimab
treatment outcome
insurance, health, reimbursement
drug combinations
antiviral agents
Pre-Exposure Prophylaxis
adult
adolescent
immunocompromised host
injections, intramuscular
tixagevimab and cilgavimab
evaluation of the transparency committee
Evusheld
COVID-19
cilgavimab and tixagevimab drug combination
---
https://www.has-sante.fr/jcms/p_3304034/fr/evusheld-tixagevimab/cilgavimab
https://has-sante.fr/jcms/p_3304078/fr/decision-n-2021-0312/dc/sem-du-9-decembre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-evusheld-tixagevimab/cilgavimab
https://www.has-sante.fr/jcms/p_3322640/fr/decision-n-2022-0071/dc/sem-du-3-mars-2022-du-college-de-la-haute-autorite-de-sante-modifiant-la-decision-n-2021-0312/dc/sem-du-9-decembre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-evusheld
2021
false
false
false
France
COVID-19
treatment outcome
Pre-Exposure Prophylaxis
adult
cilgavimab and tixagevimab drug combination
cilgavimab and tixagevimab drug combination
tixagevimab
cilgavimab
antiviral agents
injections
drug combinations
antibodies, neutralizing
evaluation of the transparency committee
---
https://ansm.sante.fr/actualites/evusheld-une-nouvelle-bitherapie-danticorps-monoclonaux-contre-la-covid-19-autorisee-en-acces-precoce
2021
false
false
false
France
French
drug information
COVID-19
Pre-Exposure Prophylaxis
cilgavimab and tixagevimab drug combination
tixagevimab
cilgavimab
antibodies, neutralizing
drug combinations
antibodies, monoclonal
antiviral agents
injections, intramuscular
treatment outcome
patient safety
adult
summary of product characteristics
package leaflet
---
